NCT01435122

A Study of Axitinib in Advanced Carcinoid Tumors

A Phase II Study of Axitinib in Advanced Carcinoid Tumors

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 30 (actual)
• Sponsor: H. Lee Moffitt Cancer Center and Research Institute · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The main purpose of this study is to see whether Axitinib will help prolong the time that the patient's carcinoid tumors remain stable, and to examine their treatment response through testing. Researchers also want to find out if Axitinib is safe and tolerable.

Detailed description

This is a bi-institutional, prospective phase II, open-label study. The target population is comprised of adult patients with histologically confirmed unresectable or metastatic carcinoid tumors. Carcinoid tumors are defined as well to moderately differentiated neuroendocrine tumors of the digestive tract and lungs. Patients with metastatic carcinoid tumors of unknown primary as well as rare primaries (renal, ovarian, thymic, hepatic) will also be eligible. Patients will be drawn from two institutions Moffitt Cancer Center (MCC) and The University of California, San Francisco (UCSF).

Conditions

• Carcinoid Tumor

Interventions

Type	Name	Description
DRUG	Axitinib	Axitinib Administration as outlined in Arm description

Timeline

• Start date: 2011-10-25
• Primary completion: 2017-01-11
• Completion: 2018-02-13
• First posted: 2011-09-15
• Last updated: 2018-10-02
• Results posted: 2017-05-25

Locations

2 sites across 1 country: United States

Regulatory

• FDA-regulated drug study